The Role of Liquid Biopsy in Hepatocellular Carcinoma Prognostication.

Published on Feb 6, 2021in Cancers6.126
· DOI :10.3390/CANCERS13040659
Ismail Labgaa15
Estimated H-index: 15
(UNIL: University of Lausanne),
Augusto Villanueva63
Estimated H-index: 63
(ISMMS: Icahn School of Medicine at Mount Sinai)
+ 2 AuthorsEmmanuel Melloul4
Estimated H-index: 4
(UNIL: University of Lausanne)
Sources
Abstract
Showing a steadily increasing cancer-related mortality, the epidemiological evolution of hepatocellular carcinoma (HCC) is concerning. Numerous strategies have attempted to prognosticate HCC but their performance is modest; this is partially due to the heterogeneous biology of this cancer. Current clinical guidelines endorse classifications and scores that use clinical variables, such as the Barcelona Clinic Liver Cancer (BCLC) classification. These algorithms are unlikely to fully recapitulate the genomic complexity of HCC. Integrating molecular readouts on a patient-basis, following a precision-medicine perspective, might be an option to refine prognostic systems. The limited access to HCC tissue samples is an important limitation to these approaches but it could be partially circumvented by using liquid biopsy. This concept consists of the molecular analysis of products derived from a solid tumor and released into biological fluids, mostly into the bloodstream. It offers an easy and minimally-invasive access to DNA, RNA, extracellular vesicles and cells that can be analyzed with next-generation sequencing (NGS) technologies. This review aims to investigate the potential contributions of liquid biopsy in HCC prognostication. The results identified prognostic values for each of the components of liquid biopsy, suggesting that this technology may help refine HCC prognostication.
📖 Papers frequently viewed together
202114.68Hepatology
7 Authors (Joseph C. Ahn, ..., Ju Dong Yang)
30 Citations
2 Citations
5 Citations
References107
Newest
#1Gabriela Hernandez-Meza (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 6
#2Johann von Felden (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 15
Last. Augusto Villanueva (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 63
view all 14 authors...
BACKGROUND Mutations in TERT promoter are established gatekeepers in early hepatocarcinogenesis, but little is known about other molecular alterations driving this process. Epigenetic deregulation is a critical event in early malignancies. Thus, we aimed: 1) to analyze DNA methylation changes during the transition from preneoplastic lesions to early HCC (eHCC) and to identify candidate epigenetic gatekeepers, and 2) to assess the prognostic potential of methylation changes in cirrhotic tissue. M...
3 CitationsSource
#1Peng-Xiang Wang (Fudan University)H-Index: 3
#2Yang Xu (Fudan University)H-Index: 34
Last. Xin-Rong Yang (Fudan University)H-Index: 35
view all 14 authors...
BACKGROUND & AIMS Liver transplantation (LTx) is one of the most effective treatments for hepatocellular carcinoma (HCC); however, tumour recurrence after LTx often leads to poor outcomes. This study investigated the value of circulating tumour cells (CTCs) as a predictor of recurrence following LTx in patients with HCC. METHODS This analysis included 193 patients with HCC who underwent LTx at our institute and accepted pre- and post-operative CTC detection; 38 were selected for serial CTC monit...
3 CitationsSource
#1Josep M. LlovetH-Index: 120
#2Robin Kate KelleyH-Index: 36
Last. Richard S. FinnH-Index: 80
view all 10 authors...
Liver cancer remains a global health challenge, with an estimated incidence of >1 million cases by 2025. Hepatocellular carcinoma (HCC) is the most common form of liver cancer and accounts for ~90% of cases. Infection by hepatitis B virus and hepatitis C virus are the main risk factors for HCC development, although non-alcoholic steatohepatitis associated with metabolic syndrome or diabetes mellitus is becoming a more frequent risk factor in the West. Moreover, non-alcoholic steatohepatitis-asso...
1,581 Citations
#1Johann von Felden (UHH: University of Hamburg)H-Index: 15
#2Amanda J. Craig (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 8
Last. Augusto Villanueva (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 63
view all 16 authors...
Little is known about the mutational landscape of advanced hepatocellular carcinoma (HCC), and predictive biomarkers of response to systemic therapies are lacking. We aimed to describe the mutational landscape of advanced HCC and to identify predictors of primary resistance to systemic therapies using circulating tumor DNA (ctDNA). We prospectively enrolled 121 patients between October 2015 and January 2019. We performed targeted ultra-deep sequencing of 25 genes and Digital Droplet PCR of TERT ...
11 CitationsSource
#1Ting Shen (Southern Medical University)H-Index: 1
#2Shan‐Feng Li (Southern Medical University)H-Index: 1
Last. De‐Ke JiangH-Index: 1
view all 17 authors...
BACKGROUND & AIMS Somatic mutation R249S in TP53 is highly common in hepatocellular carcinoma (HCC). We aim to investigate the effects of R249S in ctDNA on the prognosis of HCC. METHODS We analyzed three cohorts including 895 HCC patients. TP53 mutation spectrum was examined by direct sequencing of genomic DNA from tissue specimens in HCC patients with hepatectomy (Cohort 1, N=260). R249S and other recurrent missense mutations were assessed for their biological functions and associations with ov...
6 CitationsSource
#1Jiangmin Zhou (HUST: Huazhong University of Science and Technology)H-Index: 1
#2Zhiwei Zhang (HUST: Huazhong University of Science and Technology)H-Index: 5
Last. Xiaoping Chen (HUST: Huazhong University of Science and Technology)H-Index: 33
view all 9 authors...
BACKGROUND This study explored the diagnostic power of preoperative circulating tumor cells (CTCs) for the presence of microvascular invasion (MVI) and the relationship between dynamic changes in postoperative CTCs and prognosis. METHODS A total of 137 patients were recruited for the study. Preoperative blood samples were collected from all patients to detect CTCs. The time points for blood collection were before the operation, during the operation, and at 1 week, 1 month, 2 months, 3 months, 6 ...
4 CitationsSource
#1Stine Karlsen Oversoe (Aarhus University Hospital)H-Index: 1
#2Michelle Simone Clement (Aarhus University Hospital)H-Index: 3
Last. Jens Kelsen (Aarhus University Hospital)H-Index: 15
view all 10 authors...
Plasma circulating tumor DNA (ctDNA) with tumor-specific mutations is an attractive biomarker. The telomerase reverse transcriptase (TERT) C228T promoter mutation is the most prevalent tumor-associ...
6 CitationsSource
#1Soon Sun Kim (Ajou University)H-Index: 20
#2Jung Woo Eun (Ajou University)H-Index: 2
Last. Jae Youn Cheong (Ajou University)H-Index: 25
view all 10 authors...
Liquid biopsy can provide a strong basis for precision medicine. We aimed to identify novel single-nucleotide variants (SNVs) in circulating tumor DNA (ctDNA) in patients with hepatocellular carcinoma (HCC). Deep sequencing of plasma-derived ctDNA from 59 patients with HCC was performed using a panel of 2924 SNVs in 69 genes. In 55.9% of the patients, at least one somatic mutation was detected. Among 25 SNVs in 12 genes, four frequently observed SNVs, MLH1 (13%), STK11 (13%), PTEN (9%), and CTNN...
6 CitationsSource
#1Kai Cui (SDU: Shandong University)H-Index: 2
#1Kai Cui (SDU: Shandong University)H-Index: 3
Last. Zi-qiang SunH-Index: 1
view all 5 authors...
BACKGROUND To evaluate the clinical value of circulating tumor cell (CTC) detection in peripheral blood for the diagnosis and prognosis of hepatocellular carcinoma (HCC). METHODS Public databases were searched, and a meta-analysis was performed to determine the specificity, sensitivity, negative- likelihood ratio (NLR) and positive-likelihood ratio (PLR), and diagnostic odds ratio (dOR) of CTC detection for the diagnosis of HCC. Hazard ratios (HRs) and 95% confidence intervals (CIs) were analyze...
4 CitationsSource
#1Paul Winograd (UCLA: University of California, Los Angeles)H-Index: 6
#2Shuang Hou (UCLA: University of California, Los Angeles)H-Index: 27
Last. Vatche G. Agopian (UCLA: University of California, Los Angeles)H-Index: 27
view all 16 authors...
Hepatocellular carcinoma (HCC) is a leading cause of mortality. Checkpoint inhibitors of programmed cell death protein-1 (PD-1) and programmed death-ligand 1 (PD-L1) have shown great efficacy, but lack biomarkers that predict response. Circulating tumor cells (CTCs) have promise as a liquid-biopsy biomarker; however, data on HCC CTCs expressing PD-L1 have not been reported. We sought to detect PD-L1-expressing HCC-CTCs and investigated their role as a prognostic and predictive biomarker. Using a...
5 CitationsSource
Cited By3
Newest
#5Eduardo Andrés-León (CSIC: Spanish National Research Council)H-Index: 13
MiRNAs play a relevant role in PC (prostate cancer) by the regulation in the expression of several pathways’ AR (androgen receptor), cellular cycle, apoptosis, MET (mesenchymal epithelium transition), or metastasis. Here, we report the role of several miRNAs’ expression patterns, such as miR-miR-93-5p, miR-23c, miR-210-3p, miR-221-3p, miR-592, miR-141, miR-375, and miR-130b, with relevance in processes like cell proliferation and MET. Using Trizol® extraction protocol and TaqMan™ specific probes...
Source
#1F. PelizzaroH-Index: 2
#2Romilda CardinH-Index: 32
Last. Fabio FarinatiH-Index: 69
view all 8 authors...
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer related death worldwide. Diagnostic, prognostic, and predictive biomarkers are urgently needed in order to improve patient survival. Indeed, the most widely used biomarkers, such as alpha-fetoprotein (AFP), have limited accuracy as both diagnostic and prognostic tests. Liver biopsy provides an insight on the biology of the tumor, but it is an invasive procedure, not routinely used, and not representative of the whole neoplasia...
1 CitationsSource
#1Raphael MohrH-Index: 6
Last. Christoph RoderburgH-Index: 33
view all 10 authors...
The implementation of immune checkpoint inhibitors (ICI) into the clinical management of different malignancies has largely changed our understanding of cancer treatment. After having proven efficacy in different tumor entities such as malignant melanoma and lung cancer, ICI were intensively tested in the setting of hepatocellular carcinoma (HCC). Here they could achieve higher and more durable response rates compared to tyrosine-kinase inhibitors (TKI), that were sole standard of care for the l...
1 CitationsSource